Clinical Trials Logo

Sarcoma, Kaposi clinical trials

View clinical trials related to Sarcoma, Kaposi.

Filter by:

NCT ID: NCT00002188 Completed - HIV Infections Clinical Trials

A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).

NCT ID: NCT00002185 Completed - HIV Infections Clinical Trials

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

Start date: n/a
Phase: Phase 2
Study type: Interventional

To determine the effect of Viracept in combination with modified antiretroviral therapy on the outcome of cutaneous and mucosal Kaposi's Sarcoma (KS).

NCT ID: NCT00002167 Completed - HIV Infections Clinical Trials

Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

Start date: n/a
Phase: Phase 2
Study type: Interventional

To determine the objective tumor response and remission rate of AIDS-related Kaposi's sarcomas (KS) following a single dose of tin ethyl etiopurpurin (SnET2) followed by photodynamic therapy (PDT). To determine the systemic and local toxicity, and morbidity safety profile of SnET2-PDT.

NCT ID: NCT00002153 Completed - HIV Infections Clinical Trials

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

Start date: n/a
Phase: Phase 1
Study type: Interventional

To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma and lymphoproliferative disorders.

NCT ID: NCT00002147 Completed - HIV Infections Clinical Trials

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

Start date: n/a
Phase: Phase 3
Study type: Interventional

To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is medically indicated. Also, to evaluate the safety and efficacy of DOX-SL in patients with Kaposi's sarcoma who have previously received systemic chemotherapy with or without an anthracycline.

NCT ID: NCT00002138 Completed - HIV Infections Clinical Trials

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

Start date: n/a
Phase: Phase 1
Study type: Interventional

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

NCT ID: NCT00002137 Completed - HIV Infections Clinical Trials

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

Start date: n/a
Phase: Phase 1
Study type: Interventional

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

NCT ID: NCT00002136 Completed - HIV Infections Clinical Trials

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

Start date: n/a
Phase: Phase 1
Study type: Interventional

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

NCT ID: NCT00002131 Completed - HIV Infections Clinical Trials

A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

Start date: n/a
Phase: Phase 2
Study type: Interventional

To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related Kaposi's sarcoma.

NCT ID: NCT00002105 Completed - HIV Infections Clinical Trials

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

Start date: n/a
Phase: Phase 3
Study type: Interventional

To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy BV (bleomycin/vincristine). To evaluate the safety and tolerance of DOX-SL compared to BV in a population of AIDS patients with moderate to severe KS.